IMM40H was approved almost simultaneously by China NMPA and US FDA for clinical trial research

On August 29, 2022 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) reported that the newly developed humanized IgG1 CD70 antibody (project number: IMM40H) has been approved by the US FDA and China NMPA for Clinical trial research almost simultaneously (Press release, ImmuneOnco Biopharma, AUG 29, 2022, View Source [SID1234655666]). This is the third IND approval from the FDA so far (previously, IMM0306 and IMM2902) and it is another important milestone in clinical development of the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CD70 highly and widely expresses in many tumor tissue. Its ligand CD27 expresses on regulatory T (Treg) cells. CD70/CD27 interaction activates Treg cells which depress Tumor immunity. In vivo efficacy studies show that IMM40H has strong antitumor activities. Subcutaneously implanted tumors can be eliminated completely after 2-3 treatments at low doses.

Chairman, Founder of ImuneOnco, Dr.Tian Wenzhi said: "I am very pleased that the IMM40H we newly developed is approved by the US FDA and China NMPA for clinical trial research. We feel confident about clinical developmental value of IMM40H. We will actively promote clinical trial research and strive to bring it to the market as soon as possible, so as to benefit the cancer patients as soon as possible. "